Bristol-Myers Squibb Co. has made changes to its U.S. geographic footprint aimed at strengthening capabilities of its R&D hubs in Central NJ, the San Francisco Bay Area and Cambridge, MA, while further integrating biologics development with clinical manufacturing at key sites. Previous investments include the development of a state-of-the-art research facility in Cambridge, the expansion of its Redwood City research campus in the San Francisco and the recently opened Princeton Pike facility in Lawrenceville, NJ.

BMS will invest in the construction of a new R&D building at the Lawrenceville campus that will co-locate lab-based Discovery and Translational Medicine activities, construction at its New Brunswick, NJ facility to support biologics development, and construction to continue expansion of its biologics campus in Devens, MA.

The company also plans to initiate a phased closure of its Hopewell, NJ site by mid-2020 and will not renew its lease at the Lake Union Steam Plant site in Seattle, WA in 2019. The company has confirmed plans to close its Wallingford, CT site by the end of 2018, and it will no longer build a Connecticut Development site. The company expects many of the roles from Wallingford, Hopewell and Seattle will transition to other U.S. locations.

“These important changes to our U.S. geographic footprint will ensure we have the structural, operational and financial flexibility to deliver as effectively as possible on our mission for patients,” said Giovanni Caforio, M.D, chief executive officer, Bristol-Myers Squibb. “Today’s announcement underscores our commitment to make the right investments to continue to deliver on the promise of our pipeline and to bring transformational medicines to patients, today and in the future.”